Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve For approval of Unaudited Financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parmax Pharma Ltd has informed BSE that its Board of Directors will meet on Friday, November 14, 2025, to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2025. This is a routine regulatory filing under SEBI Listing Regulations. The company has also closed the trading window for insiders until 48 hours after the results are announced, in line with insider trading regulations. No financial figures or projections have been disclosed in this intimation.
No immediate impact on shareholders — this is a standard pre-results announcement. Investors should watch the actual Q2/H1 results on November 14 for any meaningful updates on revenue, profitability, or business outlook.